Live Breaking News & Updates on Oleculin Receives Approval In Italy To Conduct Phase 1 2 Trial Evaluating Annamycin Combination With Cytarabine Arac For The Treatment Of Acute Myeloid Leukemia Aml

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) - read this article along with other careers information, tips and advice on BioSpace ....

United States , Jenene Thomas , Gill Shephard , Walter Klemp , Liposomal Annamycin , Italian National Institute Of Health , Moleculin Biotech Inc , Drug Administration , Exchange Commission , Company Codes , Securities Exchange , Prnewswire Moleculin Biotech Inc , Italian Medicines Agency , Agenzia Italiana Del Farmaco , Istituto Superiore , Italian National Institute , Fast Track Status , Orphan Drug Designation , Moleculin Biotech , Transcription Modulator , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , High Efficacy , Oleculin Receives Approval In Italy To Conduct Phase 1 2 Trial Evaluating Annamycin Combination With Cytarabine Arac For The Treatment Of Acute Myeloid Leukemia Aml ,